Aelis Farma SA (AELIS.PA)
EUR 2.18
(2.83%)
EUR 2.18
(2.83%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 53 Thousand EUR | 51.43% |
| 2022 | 35 Thousand EUR | 105.88% |
| 2021 | 17 Thousand EUR | 1600.0% |
| 2020 | 1000.00 EUR | 504.86% |
| 2019 | -247.00 EUR | 58.21% |
| 2018 | -591.00 EUR | -795.45% |
| 2017 | -66.00 EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 1.76 Million EUR | -100.0% |
| 2024 Q1 | 1.76 Million EUR | 3237.74% |
| 2023 Q3 | 53 Thousand EUR | -44.21% |
| 2023 FY | 53 Thousand EUR | 51.43% |
| 2023 Q4 | 53 Thousand EUR | 0.0% |
| 2023 Q2 | 95 Thousand EUR | 0.0% |
| 2023 Q1 | 95 Thousand EUR | 171.43% |
| 2022 Q4 | 35 Thousand EUR | 0.0% |
| 2022 Q3 | 35 Thousand EUR | -32.69% |
| 2022 Q2 | 52 Thousand EUR | 0.0% |
| 2022 Q1 | 52 Thousand EUR | 205.88% |
| 2022 FY | 35 Thousand EUR | 105.88% |
| 2021 FY | 17 Thousand EUR | 1600.0% |
| 2021 Q2 | - EUR | 0.0% |
| 2021 Q3 | 17 Thousand EUR | 0.0% |
| 2021 Q4 | 17 Thousand EUR | 0.0% |
| 2021 Q1 | - EUR | 0.0% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 Q4 | - EUR | 0.0% |
| 2020 Q3 | - EUR | 0.0% |
| 2020 FY | 1000.00 EUR | 504.86% |
| 2019 FY | -247.00 EUR | 58.21% |
| 2018 FY | -591.00 EUR | -795.45% |
| 2017 FY | -66.00 EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ABIONYX Pharma SA | 221 Thousand EUR | 76.018% |
| ABIVAX Société Anonyme | 1.00 EUR | -5299900.0% |
| Adocia SA | 272 Thousand EUR | 80.515% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 1.74 Million EUR | 96.956% |
| genOway Société anonyme | 982.75 Thousand EUR | 94.607% |
| IntegraGen SA | 311.44 Thousand EUR | 82.983% |
| Medesis Pharma S.A. | 164.62 Thousand EUR | 67.805% |
| Neovacs S.A. | - EUR | -Infinity% |
| NFL Biosciences SA | -1.1 Million EUR | 104.781% |
| Plant Advanced Technologies SA | 1.22 Million EUR | 95.672% |
| Quantum Genomics Société Anonyme | -119.17 Thousand EUR | 144.472% |
| Sensorion SA | - EUR | -Infinity% |
| Theranexus Société Anonyme | - EUR | -Infinity% |
| TME Pharma N.V. | 91 Thousand EUR | 41.758% |
| Valbiotis SA | 1 Million EUR | 94.726% |
| TheraVet SA | 123.34 Thousand EUR | 57.03% |
| Valerio Therapeutics Société anonyme | 1.00 EUR | -5299900.0% |
| argenx SE | 281.12 Million EUR | 99.981% |
| BioSenic S.A. | - EUR | -Infinity% |
| Celyad Oncology SA | 1.26 Million EUR | 95.794% |
| DBV Technologies S.A. | 1.00 USD | -5299900.0% |
| Galapagos NV | 73.97 Million EUR | 99.928% |
| Genfit S.A. | 4000.00 EUR | -1225.0% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 1.00 EUR | -5299900.0% |
| Innate Pharma S.A. | 1.00 EUR | -5299900.0% |
| Inventiva S.A. | 417 Thousand EUR | 87.29% |
| MaaT Pharma SA | 190 Thousand EUR | 72.105% |
| MedinCell S.A. | -6.71 Million EUR | 100.789% |
| Nanobiotix S.A. | 200 Thousand EUR | 73.5% |
| Onward Medical N.V. | 936 Thousand EUR | 94.338% |
| Oryzon Genomics S.A. | 6029.00 EUR | -779.084% |
| OSE Immunotherapeutics SA | - EUR | -Infinity% |
| Oxurion NV | 128 Thousand EUR | 58.594% |
| Pharming Group N.V. | 51.38 Million EUR | 99.897% |
| Poxel S.A. | 2.95 Million EUR | 98.207% |
| GenSight Biologics S.A. | 1.00 EUR | -5299900.0% |
| Transgene SA | - EUR | -Infinity% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 1.03 Billion EUR | 99.995% |
| Valneva SE | 44.46 Million EUR | 99.881% |
| Vivoryon Therapeutics N.V. | 1.00 EUR | -5299900.0% |